HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Scientific Committee Reviewing Three UV Filters Against Endocrine-Disrupting Concerns

Executive Summary

The European Commission issued requests on 4 February for updated opinions from the Scientific Committee on Consumer Safety on octocrylene, homosalate and benzophenone-3, in light of concerns that led to their listing in 2019 as “higher priority” substances used in cosmetics with endocrine-disrupting potential.

You may also be interested in...



EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Endocrine Disruptors, The European Green Deal And The Politicization Of EU Chemical Programs

John Chave, director-general at Cosmetics Europe, says the European Commission’s plan for targeted assessment of 28 potential endocrine-disruptors in cosmetics – despite its conclusion in late 2018 that the current cosmetics regulatory framework adequately addresses endocrine-disruptor concerns – is symptomatic of a broad trend taking hold in Europe.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149725

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel